

# Michael Schultz

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8672748/publications.pdf>

Version: 2024-02-01

67  
papers

3,286  
citations

394286

19  
h-index

149623

56  
g-index

67  
all docs

67  
docs citations

67  
times ranked

4368  
citing authors

#	ARTICLE	IF	CITATIONS
1	Assessment of source material for human intestinal organoid culture for research and clinical use. BMC Research Notes, 2022, 15, 35.	0.6	1
2	A Short Knowledge Assessment Tool Is Valid and Acceptable for Adults with Inflammatory Bowel Disease. Digestive Diseases and Sciences, 2022, , 1.	1.1	3
3	Diagnostic Delay in Paediatric Inflammatory Bowel Disease—A Systematic Investigation. Journal of Clinical Medicine, 2022, 11, 4161.	1.0	4
4	ABC score: a new risk score that accurately predicts mortality in acute upper and lower gastrointestinal bleeding: an international multicentre study. Gut, 2021, 70, 707-716.	6.1	77
5	Physical Activity in Patients with Inflammatory Bowel Disease: A Cross-Sectional Study. Inflammatory Intestinal Diseases, 2021, 6, 61-69.	0.8	12
6	Perceived versus objective sleep quality in long-stay hospitalised older adults—a mixed methods study. Age and Ageing, 2021, 50, 955-962.	0.7	6
7	Can Coupling Multiple Complementary Methods Improve the Spectroscopic Based Diagnosis of Gastrointestinal Illnesses? A Proof of Principle <i>Ex Vivo</i> Study Using Celiac Disease as the Model Illness. Analytical Chemistry, 2021, 93, 6363-6374.	3.2	6
8	Adherence to Inflammatory Bowel Disease Medications in Southern New Zealand. Crohn's & Colitis 360, 2021, 3, .	0.5	4
9	Barriers to international travel in inflammatory bowel disease patients. Journal of Travel Medicine, 2021, 28, .	1.4	5
10	Attitudes towards and use of cannabis in New Zealand patients with inflammatory bowel disease: an exploratory study. New Zealand Medical Journal, 2021, 134, 38-47.	0.5	0
11	MURAL: An Unsupervised Random Forest-Based Embedding for Electronic Health Record Data. , 2021, , .		1
12	Validation of a Machine Learning Model That Outperforms Clinical Risk Scoring Systems for Upper Gastrointestinal Bleeding. Gastroenterology, 2020, 158, 160-167.	0.6	133
13	A Noninferiority Randomized Clinical Trial of the Use of the Smartphone-Based Health Applications IBDsmart and IBDoc in the Care of Inflammatory Bowel Disease Patients. Inflammatory Bowel Diseases, 2020, 26, 1098-1109.	0.9	31
14	Evaluation of lactulose, lactose, and fructose breath testing in clinical practice: A focus on methane. JGH Open, 2020, 4, 198-205.	0.7	12
15	MAP(ASH): A new scoring system for the prediction of intervention and mortality in upper gastrointestinal bleeding. Journal of Gastroenterology and Hepatology (Australia), 2020, 35, 82-89.	1.4	23
16	Simplified monitoring for hepatitis C virus treatment with glecaprevir plus pibrentasvir, a randomised non-inferiority trial. Journal of Hepatology, 2020, 72, 431-440.	1.8	30
17	Infliximab trough levels: A comparison between the Quantum Blue Infliximab assay and the established ELISA. Journal of Gastroenterology and Hepatology (Australia), 2020, 35, 1302-1306.	1.4	5
18	Quality of life in postostomy surgery patients: A cross-sectional survey. JGH Open, 2020, 4, 987-994.	0.7	5

#	ARTICLE	IF	CITATIONS
19	Patients' accounts of living with and managing inflammatory bowel disease in rural Southern New Zealand: a qualitative study. <i>BMJ Open</i> , 2020, 10, e041789.	0.8	6
20	Challenges for the future: the gastroenterology specialist workforce in New Zealand. <i>New Zealand Medical Journal</i> , 2020, 133, 32-40.	0.5	0
21	Successful use of generic direct acting antiviral medications to treat hepatitis C-a New Zealand-wide study. <i>New Zealand Medical Journal</i> , 2020, 133, 53-61.	0.5	0
22	Infliximab and adalimumab concentrations and anti-drug antibodies in inflammatory bowel disease control using New Zealand assays. <i>Internal Medicine Journal</i> , 2019, 49, 513-518.	0.5	8
23	Association of Genetic Variants in <i>NUDT15</i> With Thiopurine-Induced Myelosuppression in Patients With Inflammatory Bowel Disease. <i>JAMA - Journal of the American Medical Association</i> , 2019, 321, 773.	3.8	129
24	How much force is required to perforate a colon during colonoscopy? An experimental study. <i>Journal of the Mechanical Behavior of Biomedical Materials</i> , 2019, 91, 139-148.	1.5	10
25	Identifying barriers to treatment of HCV in the primary care setting. <i>Hepatology International</i> , 2019, 13, 58-65.	1.9	15
26	Previous Use of Antithrombotic Agents Reduces Mortality and Length of Hospital Stay in Patients With High-risk Upper Gastrointestinal Bleeding. <i>Clinical Gastroenterology and Hepatology</i> , 2019, 17, 440-447.e2.	2.4	22
27	Intestinal Organoids as a Tool for Inflammatory Bowel Disease Research. <i>Frontiers in Medicine</i> , 2019, 6, 334.	1.2	44
28	New Zealand Society of Gastroenterology Guidelines on Therapeutic Drug Monitoring in Inflammatory Bowel Disease. <i>New Zealand Medical Journal</i> , 2019, 132, 46-62.	0.5	0
29	Severity and Outcomes of Upper Gastrointestinal Bleeding With Bloody Vs. Coffee-Grounds Hematemesis. <i>American Journal of Gastroenterology</i> , 2018, 113, 358-366.	0.2	19
30	The risk of non-melanoma skin cancer in New Zealand in inflammatory bowel disease patients treated with thiopurines. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2018, 33, 1047-1052.	1.4	9
31	Detailed Multi-Dimensional Assessment of Fatigue in Inflammatory Bowel Disease. <i>Inflammatory Intestinal Diseases</i> , 2018, 3, 192-202.	0.8	16
32	OWE-006...Should we be using the shock index to assess patients presenting with upper GI bleeding?. , 2018, , .		0
33	Annual Incidence and Phenotypic Presentation of IBD in Southern New Zealand: An 18-Year Epidemiological Analysis. <i>Inflammatory Intestinal Diseases</i> , 2018, 3, 32-39.	0.8	13
34	A liver health hui: hepatitis C knowledge and associated risk factors in New Zealand gang members and their families. <i>Royal Society Open Science</i> , 2018, 5, 172167.	1.1	0
35	Cervical vagus nerve morphometry and vascularity in the context of nerve stimulation - A cadaveric study. <i>Scientific Reports</i> , 2018, 8, 7997.	1.6	57
36	PTH-119...International multicentre study of mallory weiss tear related gi bleeding: demographics, endoscopic therapy and outcome. , 2018, , .		0

#	ARTICLE	IF	CITATIONS
37	Audit of the association between length of time spent on diagnostic work-up and tumour stage in patients with symptomatic colon cancer. ANZ Journal of Surgery, 2017, 87, 138-142.	0.3	11
38	Relationship of time to presentation after onset of upper GI bleeding with patient characteristics and outcomes: a prospective study. Gastrointestinal Endoscopy, 2017, 86, 1028-1037.	0.5	13
39	“We are what our bacteria eat”. The role of bacteria in personalizing nutrition therapy in gastrointestinal conditions. Journal of Gastroenterology and Hepatology (Australia), 2017, 32, 352-357.	1.4	7
40	Comparison of risk scoring systems for patients presenting with upper gastrointestinal bleeding: international multicentre prospective study. BMJ, The, 2017, 356, i6432.	3.0	247
41	Long-term irritable bowel syndrome symptom control with reintroduction of selected FODMAPs. World Journal of Gastroenterology, 2017, 23, 4632.	1.4	94
42	Awareness of coeliac disease among chefs and cooks depends on the level and place of training. Asia Pacific Journal of Clinical Nutrition, 2017, 26, 719-724.	0.3	7
43	Incidence and features of eosinophilic esophagitis in dysphagia: a prospective observational study. Scandinavian Journal of Gastroenterology, 2016, 51, 257-262.	0.6	15
44	Distinct immune signatures in the colon of Crohn's disease and ankylosing spondylitis patients in the absence of inflammation. Immunology and Cell Biology, 2016, 94, 421-429.	1.0	7
45	Family history assessment for colorectal cancer (CRC) risk analysis - comparison of diagram- and questionnaire-based web interfaces. BMC Medical Informatics and Decision Making, 2015, 15, 95.	1.5	5
46	Does Preendoscopy Rockall Score Safely Identify Low Risk Patients following Upper Gastrointestinal Haemorrhage?. Gastroenterology Research and Practice, 2015, 2015, 1-7.	0.7	2
47	Use of pethidine for percutaneous liver biopsy “ a randomised, placebo-controlled, double blind study. BMC Gastroenterology, 2015, 15, 33.	0.8	4
48	Aggravation of Established Colitis in Specific Pathogen-free IL-10 Knockout Mice by Restraint Stress Is Not Mediated by Increased Colonic Permeability. Journal of Crohn's and Colitis, 2015, 9, 754-762.	0.6	9
49	Performance of New Thresholds of the Glasgow Blatchford Score in Managing Patients With Upper Gastrointestinal Bleeding. Clinical Gastroenterology and Hepatology, 2015, 13, 115-121.e2.	2.4	92
50	Prevalence and knowledge of hepatitis C in a middle-aged population, Dunedin, New Zealand. World Journal of Gastroenterology, 2015, 21, 10224-10233.	1.4	11
51	Chronic Exposure To Microbial Stimuli Affects The Development Of The Intestinal Epithelium In Human Colonic Enteroids. FASEB Journal, 2015, 29, 999.7.	0.2	1
52	Field test of a questionnaire-based mobile health reporting system. , 2014, , .		1
53	Do high risk patients alter their lifestyle to reduce risk of colorectal cancer?. BMC Gastroenterology, 2014, 14, 22.	0.8	7
54	Immunomodulators in Inflammatory Bowel Disease: An Emerging Role for Biologic Agents. BioDrugs, 2013, 27, 585-590.	2.2	21

#	ARTICLE	IF	CITATIONS
55	Inflammation reduces the response to forskolin and expression of the NaHCO <sub>3</sub> cotransporter, NBCe1, in the proximal colon of IL10 <sup>-/-</sup> mice. <i>FASEB Journal</i> , 2013, 27, .	0.2	0
56	Perceived risks and benefits of surveillance colonoscopy in people undergoing surveillance for family history of colorectal cancer. <i>New Zealand Medical Journal</i> , 2013, 126, 58-69.	0.5	1
57	Is the north to south gradient in inflammatory bowel disease a global phenomenon?. <i>Expert Review of Gastroenterology and Hepatology</i> , 2012, 6, 445-447.	1.4	26
58	Testing probiotic strain <i>Escherichia coli</i> Nissle 1917 (Mutaflor) for its ability to reduce carriage of multidrug-resistant <i>E. coli</i> by elderly residents in long-term care facilities. <i>Journal of Medical Microbiology</i> , 2011, 60, 366-370.	0.7	45
59	Consumer demographics and expectations of probiotic therapy in New Zealand: results of a large telephone survey. <i>New Zealand Medical Journal</i> , 2011, 124, 36-43.	0.5	9
60	New Zealand Society of Gastroenterology statement on the use of biological therapy in inflammatory bowel disease. <i>New Zealand Medical Journal</i> , 2010, 123, 134-44.	0.5	1
61	Gastroenterology service in a teaching hospital in rural New Zealand, 1991-2003. <i>World Journal of Gastroenterology</i> , 2009, 15, 583.	1.4	3
62	Clinical use of <i>E. coli</i> Nissle 1917 in inflammatory bowel disease. <i>Inflammatory Bowel Diseases</i> , 2008, 14, 1012-1018.	0.9	244
63	Rationale for probiotic treatment strategies in inflammatory bowel disease. <i>Expert Review of Gastroenterology and Hepatology</i> , 2008, 2, 337-355.	1.4	20
64	Post-procedure surveillance in liver biopsy: how long is long enough?. <i>New Zealand Medical Journal</i> , 2008, 121, 8-14.	0.5	3
65	<i>Lactobacillus plantarum</i> 299V in the Treatment and Prevention of Spontaneous Colitis in Interleukin-10-Deficient Mice. <i>Inflammatory Bowel Diseases</i> , 2002, 8, 71-80.	0.9	325
66	Resident Enteric Bacteria Are Necessary for Development of Spontaneous Colitis and Immune System Activation in Interleukin-10-Deficient Mice. <i>Infection and Immunity</i> , 1998, 66, 5224-5231.	1.0	1,346
67	<i>Escherichia coli</i> . , 0, , 83-96.		3